News & Analysis as of

Johnson & Johnson Bayer

Patrick Malone & Associates P.C. | DC Injury...

As J&J ‘trims’ talc loss to $2.1 billion, Bayer sees $10-billion-plus Roundup fix

Leave it to corporations, even with the pressure of the civil justice system, to figure billions of ways to never say they are sorry — and to leave consumers hanging about problematic products and practices....more

Searcy Denney Scarola Barnhart & Shipley

Plaintiff Awarded $27.8 Million in First Xarelto Pennsylvania State Trial

On Tuesday, a jury entered a verdict of $27.8 million against Johnson & Johnson’s Janssen Pharmaceuticals, Inc. and Bayer AG’s Bayer Pharmaceuticals Inc. in the first state court trial out of the Philadelphia County Court of...more

Searcy Denney Scarola Barnhart & Shipley

Xarelto’s Approval by the FDA

The controversy over Xarelto’s approval by the FDA and alleged irregularities in the conduct of the ROCKET-AF clinical trial continue to hang over the heads of Bayer and Janssen (a division of Johnson & Johnson), the...more

Searcy Denney Scarola Barnhart & Shipley

Xarelto Litigation — An Update

On February 23, 2016, Judge Fallon held another status conference in the national litigation over Xarelto. There are now over 5,600 individual lawsuits pending in MDL No. 2952, the coordinated federal court proceedings...more

Searcy Denney Scarola Barnhart & Shipley

Xarelto Litigation – February Updates

There have been a number of recent noteworthy developments in the national litigation involving Xarelto. Currently, there are approximately 5,000 individual lawsuits pending in state and federal courts against the...more

Searcy Denney Scarola Barnhart & Shipley

June Xarelto Update – Science Day

Judge Fallon, the federal judge in New Orleans who oversees the MDL coordinated proceedings, held his most recent hearing for all of the pending Xarelto lawsuits on June 10, 2015. At that time, the judge was provided with a...more

Searcy Denney Scarola Barnhart & Shipley

Xarelto Suits Sent to Louisiana

Xarelto (rivaroxaban) is a new generation anticoagulant in a class of drugs known as direct thrombin inhibitors. It is a blood thinner used to reduce the risk of blood clots and strokes. Xarelto has also been marketed as...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide